--- title: "Inovio Pharmaceuticals (INO) news: class action and offering" url: "https://aibio.space/companies/inovio-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "INO class action and offering news: Inovio faces securities class action and five derivative suits over INO-3107 statements. Inovio Pharmaceuticals, Inc." --- INO Inovio Pharmaceuticals, Inc. NASDAQ · United States # Inovio Pharmaceuticals (INO) news INO class action and offering news Legal · 2026-10-06 ## [Inovio faces securities class action and five derivative suits over INO-3107 statements](https://aibio.space/news/inovio-faces-securities-class-action-five-derivative-suits-ino-3107/) Inovio, CEO Jacqueline Shea and CFO Peter Kies are defendants in a Pennsylvania class action. Shea, Kies and seven directors are named in derivative suits. A lead plaintiff was appointed July 27, 2026. ## Latest Inovio Pharmaceuticals news 1. 2026-08-12 Legal [Inovio's supply-contract suit against VGXI and GeneOne is set for trial in October 2026](https://aibio.space/news/inovios-supply-contract-suit-against-vgxi-geneone-set-trial-october/) Inovio sued VGXI, Inc. and GeneOne Life Science, Inc. in a Pennsylvania state court in 2020 over a supply agreement. The defendants counterclaimed. A seven-day trial was scheduled to begin October 13, 2026. 2. 2024-12-12 Financings [Inovio Pharmaceuticals prices $30 million offering of stock and warrants at $3.00](https://aibio.space/news/inovio-pharmaceuticals-prices-30-million-offering-stock-warrants-3-00/) Inovio is selling 10,000,000 shares at $3.00 with warrants for 10,000,000 more shares at $3.76. The filing gives net proceeds of about $27.6 million and immediate dilution of $0.19 per share. ## Inovio Pharmaceuticals at a glance - **Ticker**: INO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $36.7 million ### Related companies - [Pasithea Therapeutics](https://aibio.space/companies/pasithea-therapeutics/) NASDAQ: KTTA - [Turn Therapeutics](https://aibio.space/companies/turn-therapeutics/) NASDAQ: TTRX - [Puma Biotechnology](https://aibio.space/companies/puma-biotechnology/) NASDAQ: PBYI - [Ardelyx](https://aibio.space/companies/ardelyx/) NASDAQ: ARDX - [Inhibikase Therapeutics](https://aibio.space/companies/inhibikase-therapeutics/) NASDAQ: IKT - [BlossomHill Therapeutics](https://aibio.space/companies/blossomhill-therapeutics/) NASDAQ: BLSM - [Pyxis Oncology](https://aibio.space/companies/pyxis-oncology/) NASDAQ: PYXS - [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) NASDAQ: ACTU ### Also on NASDAQ - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) CLRB - [CAMP4 Therapeutics](https://aibio.space/companies/camp4-therapeutics/) CAMP - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) ANTX - [Acrivon Therapeutics](https://aibio.space/companies/acrivon-therapeutics/) ACRV - [Kardigan](https://aibio.space/companies/kardigan/) KARD - [Achieve Life Sciences](https://aibio.space/companies/achieve-life-sciences/) ACHV ## What Inovio Pharmaceuticals does Inovio Pharmaceuticals, Inc. develops DNA medicines for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases, along with proprietary electroporation devices used to deliver them. Its product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic. Its most advanced program, INO-3107, is a DNA medicine for adults with RRP. In December 2025 the FDA accepted the company's BLA for INO-3107 for review under the accelerated approval program. The FDA granted a standard 10-month review rather than priority review, with a PDUFA target date of October 30, 2026. The FDA has noted as a potential review issue its preliminary conclusion that the company had not provided adequate information to justify eligibility for accelerated approval, and the FDA has agreed to meet with the company. The company has a small commercial organization and no in-house sales team. Its text also cites collaborations with Chinese companies, agreements with government agencies that may be terminated, and substantial doubt about its ability to continue as a going concern. | Product or program | What it is | Stage | |---|---|---| | INO-3107 | DNA medicine for adults with RRP under accelerated approval review | BLA accepted; PDUFA target date October 30, 2026 | | CELLECTRA delivery devices | Electroporation devices used to deliver DNA medicines | marketing authorization required | Summarised from the company's [10-K filed Mar 12, 2026](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm). ## Inovio Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$54.2 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/) | [$75.6 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/) | | Net income (loss) | [-$84.9 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/) | [-$107.3 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/) | | Cash from operations | [-$88.6 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/) | [-$104.1 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/) | | Cash and equivalents | [$44.3 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000023/) | [$65.8 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/) | | Short-term investments | [$14.2 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000023/) | [$28.3 million](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $31.5 million, plus short-term investments of $5.1 million, $36.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Inovio Pharmaceuticals Is there a class action against Inovio Pharmaceuticals? Our latest story on this, dated Oct 6, 2026: "Inovio faces securities class action and five derivative suits over INO-3107 statements". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inovio-faces-securities-class-action-five-derivative-suits-ino-3107/). Has Inovio Pharmaceuticals raised money recently? Our latest story on this, dated Dec 12, 2024: "Inovio Pharmaceuticals prices $30 million offering of stock and warrants at $3.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inovio-pharmaceuticals-prices-30-million-offering-stock-warrants-3-00/). What is the ticker symbol of Inovio Pharmaceuticals? Inovio Pharmaceuticals, Inc. trades under the ticker INO on NASDAQ. Where is Inovio Pharmaceuticals listed? Inovio Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:INO; BMV:INO; GETTEX:GBM; LS:A400EJ; LSE:0A43; LSX:A400EJ. What is the SEC CIK of Inovio Pharmaceuticals? The SEC Central Index Key (CIK) for Inovio Pharmaceuticals, Inc. is 1055726. Its filings are on SEC EDGAR. How many shares does Inovio Pharmaceuticals have outstanding? 103,397,518 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Inovio Pharmaceuticals listed under? Our directory records Inovio Pharmaceuticals, Inc. under United States. What does Inovio Pharmaceuticals do? Our directory classifies Inovio Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Inovio Pharmaceuticals? The ISIN recorded for Inovio Pharmaceuticals, Inc. is US45773H4092. Does aibio.space cover Inovio Pharmaceuticals? aibio.space lists Inovio Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Inovio Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Inovio Pharmaceuticals develop? Inovio Pharmaceuticals, Inc. develops DNA medicines for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases, along with proprietary electroporation devices used to deliver them. Its product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic. What is INO-3107 from Inovio Pharmaceuticals? INO-3107: DNA medicine for adults with RRP under accelerated approval review Stage: BLA accepted; PDUFA target date October 30, 2026. What is CELLECTRA delivery devices from Inovio Pharmaceuticals? CELLECTRA delivery devices: Electroporation devices used to deliver DNA medicines Stage: marketing authorization required. Is Inovio Pharmaceuticals profitable? Inovio Pharmaceuticals, Inc. reported a net loss of $84.9 million for the fiscal year ended Dec 31, 2025, and used $88.6 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Inovio Pharmaceuticals Members talk about Inovio Pharmaceuticals (INO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Inovio Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-07-02 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1055726/000119312526294457/d141328ds3.htm) 2. 2026-03-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm) 3. 2025-11-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1055726/000119312525274790/d10087d424b5.htm) 4. 2024-12-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1055726/000119312524277193/d876750d424b5.htm) 5. 2024-11-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1055726/000105572624000052/ino-20240930.htm) ## Press releases Headlines of Inovio Pharmaceuticals's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-30 PR Newswire [INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)](https://www.prnewswire.com/news-releases/inovio-announces-fda-accelerated-approval-of-voceryq-an-immunotherapy-to-reduce-the-frequency-of-surgery-in-adults-with-recurrent-respiratory-papillomatosis-rrp-302925406.html) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INO on TradingView](https://www.tradingview.com/symbols/NASDAQ-INO/). ## SEC filings and registration - **SEC name**: Inovio Pharmaceuticals, Inc. - **CIK**: 1055726 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: INO (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462 - **Phone**: 8584103134 - **Shares outstanding**: 103,397,518 as of 2026-08-10 (10-Q filed 2026-08-12) - **Former names**: INOVIO BIOMEDICAL CORP; GENETRONICS BIOMEDICAL CORP; GENETRONICS BIOMEDICAL LTD ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1055726/000119312526415555/d127604d8k.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-20260812.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000023/ino-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1055726/000119312526326785/d253972d8k.htm) filed 2026-07-31 - [424B5](https://www.sec.gov/Archives/edgar/data/1055726/000119312526326370/d155272d424b5.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1055726/000119312526323628/d158934d8k.htm) filed 2026-07-29 - [424B5](https://www.sec.gov/Archives/edgar/data/1055726/000119312526323616/d155272d424b5.htm) filed 2026-07-29 - [S-3](https://www.sec.gov/Archives/edgar/data/1055726/000119312526294457/d141328ds3.htm) filed 2026-07-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001055726), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Inovio Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Inovio Pharmaceuticals, Inc. - **Ticker**: INO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US45773H4092 - **Other listed symbols**: BIVA:INO; BMV:INO; GETTEX:GBM; LS:A400EJ; LSE:0A43; LSX:A400EJ - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-INO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/inovio-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Inovio Pharmaceuticals (INO) news: class action and offering", 2026-10-31, https://aibio.space/companies/inovio-pharmaceuticals/